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We screened 145 HIV-infected non-pregnant women at a tertiary care centre in Lusaka, Zambia. Liquid-based cytology and human
papillomavirus (HPV) genotyping with PGMY09/11 biotinylated primers (Roche Linear Array
s HPV genotyping test) maximised
sensitivity of cytology and HPV assessments. Among high-risk (HR) types, HPV 52 (37.2%), 58 (24.1%) and 53 (20.7%) were more
common overall than HPV 16 (17.2%) and 18 (13.1%) in women with high-grade squamous intraepithelial lesions or squamous cell
carcinoma (SCC) on cytology. High-risk HPV types were more likely to be present in women with CD4
þ cell counts o200ml
 1
(odds ratios (OR): 4.9, 95% confidence intervals (CI): 1.4–16.7, P¼0.01) and in women with high-grade or severe cervical cytological
abnormalities (OR: 8.0, 95% CI: 1.7–37.4, P¼0.008). Human papillomavirus diversity in high-grade lesions and SCC on cytology
suggests that HPV 16- and 18-based vaccines may not be adequately polyvalent to induce protective immunity in this population.
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Increasing numbers of HIV-infected women in sub-Saharan
African settings like Zambia are now accessing life-prolonging
antiretroviral therapy (ART) (Stringer et al, 2006). The conse-
quently increasing lifespan may increase their risk of such
malignancies as cervical cancer (Strickler et al, 2005). In a cross-
sectional study among HIV-infected women seeking ART in
Lusaka, Zambia, we reported a 79% prevalence of high-grade
squamous intraepithelial lesions (HSIL) of the cervix (Parham
et al, 2006). The presence of high-risk (HR) human papillomavirus
(HPV) types was independently associated with high-grade
cytological lesions (adjusted odds ratios (OR): 12.4, 95%
confidence intervals (CI): 2.6–58.1, P¼0.02). We were able to
study HPV genotypes on stored samples from these women.
MATERIALS AND METHODS
We enrolled 150 consecutive, consenting, non-pregnant HIV-
infected Zambian women seeking HIV/AIDS treatment and care
at the University Teaching Hospital, the largest tertiary-level care
centre in the capital of Lusaka. All women provided written,
informed consent and the study was approved by the Research
Ethics Committee of the University of Zambia and the Institutional
Review Board of the University of Alabama at Birmingham.
Participants underwent a complete physical and gynaecological
evaluation and cervical samples were collected using Ayre’s spatula
for the ectocervix and cytobrush for the endocervix. Samples were
stored in vials containing PreservCyt
s transport medium (Cytyc
Corporation, Marlborough, MA, USA) at room temperature (371C)
for o2 weeks before being batch transported for cytological analysis.
Slides prepared from the PreservCyt
s vials were analysed by
the liquid-based ThinPrep
s cytological imaging system (Cytyc
Corporation, Marlborough, MA, USA). All slides were initially
screened by a senior cytotechnologist and all abnormal results and
10% of negatives were subsequently reviewed by a board-certified
cytopathologist. The cytology results were classified
and reported as no abnormality detected (normal), atypical
squamous cells of undetermined significance (ASCUS), low-grade
squamous intraepithelial lesions (LSIL), HSIL and suspicious for
squamous cell carcinoma (SCC).
We performed HPV typing by polymerase chain reaction (PCR)-
based amplification of target DNA using the Linear Array
s HPV
genotyping test (LA-HPV) (Roche Molecular Systems, Pleasanton,
CA, USA), an enhanced and commercialised version of the PGMY
line blot assay (PGMY-LB) (Coutlee et al, 2002, 2006; Kornegay
et al, 2003). The pool of consensus L1 PGMY09/11 primers used in
this assay is designed to amplify HPV-DNA from 37 genotypes.
These include HR HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 73, 82), low risk (LR) types (6, 11, 40, 42, 54,
55, 61, 70, 72, 81, and CP6108), and types with unknown risk (UR)
(62, 64, 67, 69, 71, 83, 84, and IS39). Human papillomavirus types
26, 53, and 66 are usually classified as ‘probable’ HR types (Munoz
et al, 2003), but were grouped with other HR types in this analysis
to simplify interpretation.
All participants underwent visual inspection of the cervix with
acetic acid and diagnostic colposcopy during the same clinic visit.
A CD4
þ cell enumeration was performed with a Beckman Coulter
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yEpics XL-MCL 4-color Flow Cytometer (Beckman Coulter Inc.
Miami, FL, USA) during the same visit unless a result was available
within 3 weeks of the visit date from our rigorously certified
laboratory (through the quality assurance programme of the HIV
Prevention Trials Network of the National Institute of Allergy and
Infectious Diseases, USA).
Using unconditional logistic regression to calculate prevalence
OR and 95% CIs, we compared the type-specific HPV prevalence in
HIV-infected women with CD4
þ cell counts o200ml
 1 against
those of women with CD4
þ cell counts X200ml
 1, the threshold to
make clinical decisions for initiating ART in persons without
symptoms in Zambia. Similarly, we calculated OR and 95% CIs for
comparing the type-specific HPV prevalence in women with HSIL
or SCC on cervical cytology and those with lower grade (ASCUS,
LSIL) or no cytologic abnormalities. Statistical analysis was carried
out using SPSS 14.0 for Windows
t (SPSS Inc, Chicago, IL, USA).
We restricted our analysis to 145 participants with complete data
both on CD4
þ cell counts and individual HPV genotypes.
RESULTS
The mean and median ages of these 145 participants were 36.2
years (s.d.: 76.3) and 36 years (IQR: 31–41), respectively. About a
Table 1 Associations between prevalent human papillomavirus (HPV) types and CD4
+ lymphocyte counts and cervical cytological abnormalities among
HIV-infected Zambian women
CD4
+ cell count o200/ll( n¼91) HSIL or SCC on cytology (n¼77)
HPV-type
categories N (% of 145) HPV +ve
OR (95% CI) (compared
to CD4
+ X200/ll) P-value HPV +ve
OR (95% CI) (Compared to LSIL or
less severe lesions on cytology) P-value
Presence of various categories of HPV types
Any HR 131(90.3%) 87 4.9 (1.4–16.7) 0.01 75 8.0 (1.7–37.4) 0.008
Any LR 87 (60%) 57 1.3 (0.67–2.7) 0.4 45 0.87 (0.45–1.7) 0.7
Any UR 87 (60%) 60 1.9 (0.97–3.9) 0.06 45 0.87 (0.45–1.7) 0.7
Multiple 127 (87.6%) 83 1.4 (0.46–4.3) 0.5 71 1.7 (0.55–5.2) 0.4
Presence of individual high-risk HPV types (in order of decreasing prevalence)
HPV 52
a 54 (37.2%) 39 1.9 (0.94–4.0) 0.07 32 1.5 (0.75–2.9) 0.3
HPV 58 35 (24.1%) 24 1.4 (0.62–3.1) 0.4 25 2.8 (1.2–6.3) 0.02
HPV 53 30 (20.7%) 20 1.2 (0.53–2.9) 0.6 17 1.2 (0.53–2.7) 0.7
HPV 16 25 (17.2%) 14 0.71 (0.27–1.9) 0.4 17 2.1 (0.85–5.3) 0.1
HPV 35 25 (17.2%) 18 1.7 (0.64–4.3) 0.3 14 1.1 (0.48–2.7) 0.8
HPV 45 25 (17.2%) 19 2.1 (0.73–6.4) 0.1 17 2.1 (0.85–5.3) 0.1
HPV 51 22 (15.2%) 18 3.1 (0.98–9.6) 0.05 15 2.1 (0.80–5.5) 0.1
HPV 66 21 (14.5%) 14 1.2 (0.46–3.2) 0.7 9 0.62 (0.24–1.6) 0.3
HPV 31 21 (14.5%) 14 1.2 (0.45–3.2) 0.7 16 3.3 (1.1–9.6) 0.03
HPV 68 20 (13.8%) 15 1.9 (0.66–5.7) 0.2 11 1.1 (0.42–2.8) 0.9
HPV 18 19 (13.1%) 12 1.0 (0.34–3.1) 0.97 10 0.98 (0.37–2.6) 0.96
HPV 39 18 (12.4%) 15 3.4 (0.92–12.8) 0.07 11 1.4 (0.53–4.0) 0.5
HPV 56 18 (12.4%) 13 1.6 (0.55–4.9) 0.4 11 1.4 (0.53–4.0) 0.5
HPV 33 12 (8.3%) 10 3.2 (0.67–15.2) 0.1 8 1.8 (0.53–6.5) 0.3
HPV 59 12 (8.3%) 5 0.39 (0.12–1.3) 0.1 5 0.60 (0.18–2.0) 0.4
HPV 52
b 11 (7.6%) 8 1.6 (0.41–6.5) 0.5 4 0.48 (0.13–1.7) 0.3
HPV 73 10 (6.9%) 7 1.4 (0.35–5.7) 0.6 4 0.57 (0.15–2.1) 0.4
HPV 26 9 (6.2%) 7 2.2 (0.43–10.8) 0.4 7 3.3 (0.66–16.5) 0.1
HPV 82 7 (4.8%) 5 1.5 (0.28–8.1) 0.6 5 2.3 (0.43–12.2) 0.3
Presence of individual low-risk HPV types (in order of decreasing prevalence)
HPV 61 39 (26.9%) 25 1.1 (0.50–2.3) 0.8 19 0.79 (0.38–1.6) 0.5
HPV 81 26 (17.9%) 17 1.1 (0.47–2.8) 0.8 14 1.0 (0.44–2.4) 0.9
CP 6108 20 (13.8%) 14 1.4 (0.52–4.0) 0.5 9 0.69 (0.27–1.8) 0.4
HPV 70 18 (12.4%) 11 0.92 (0.33–2.5) 0.9 10 1.12 (0.41–3.0) 0.8
HPV 42 17 (11.7%) 11 1.1 (0.38–3.2) 0.9 8 0.76 (0.28–2.1) 0.6
HPV 72 13 (8.9%) 11 3.6 (0.76–16.8) 0.1 6 0.74 (0.23–2.3) 0.6
HPV 54 12 (8.3%) 8 1.2 (0.34–4.2) 0.8 5 0.60 (0.18–2.0) 0.4
HPV 40 9 (6.2%) 5 0.72 (0.18–2.8) 0.7 4 0.69 (0.18–2.7) 0.6
HPV 6 5 (3.4%) 5 1 (—) — 3 1.4 (0.22–8.2) 0.8
HPV 11 1 (0.7%) 1 1 (—) — 0 — —
Presence of individual unknown-risk HPV types (in order of decreasing prevalence)
HPV 62 37 (25.5%) 24 1.1 (0.52–2.5) 0.8 24 1.9 (0.88–4.1) 0.1
HPV 84 26 (17.9%) 18 1.4 (0.57–3.5) 0.5 13 0.86 (0.37–2.0) 0.7
HPV 71 23 (15.9%) 19 3.3 (1.1–10.3) 0.04 14 1.5 (0.59–3.6) 0.4
HPV 83 16 (11.0%) 11 1.3 (0.44–4.1) 0.6 6 0.49 (0.17–1.4) 0.2
HPV 55 14 (9.7%) 12 3.9 (0.85–18.4) 0.08 6 0.63 (0.21–1.9) 0.4
HPV 67 9 (6.2%) 6 1.2 (0.29–5.0) 0.8 5 1.1 (0.29–4.3) 0.9
IS 39 8 (5.5%) 5 0.98 (0.23–4.3) 0.98 4 0.88 (0.21–3.6) 0.9
HPV 69 2 (1.4%) 1 0.59 (0.03–9.6) 0.7 1 0.88 (0.05–14.4) 0.9
HPV 64 0 (0%) 0 — — 0 — —
HSIL¼high-grade squamous intraepithelial lesions; SCC¼squamous cell carcinoma; LSIL¼low-grade squamous intraepithelial lesions; HR¼high-risk HPV types; LR¼low-risk
HPV types; UR: HPV types of unknown risk.
aand
b: Probe for detection of HPV 52 cross reacts with HPV 33, 35, and 58. Thus,
ais HPV 52 with HPV type 33, 35, and/or 58
coinfection while
bis HPV 52 present without any coinfection.
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husband, just under a half were educated beyond high school (70
out of 145, 48.3%) and a majority (84 out of 138, 57.9%) reported a
family income of less than 500000 Zambian kwacha (BUS$110)
per month. Little over a third (54 out of 144, 37.2%) reported their
age of first sexual intercourse as less than 18 years, and 116 out of
145 (80%) reported between one and five lifetime sexual partners.
Nine (6.2%) women had cytologic results within normal limits.
Atypical squamous cells of undetermined significance was
reported in 25 (17.2%), LSIL in 34 (23.5%), HSIL in 49 (33.8%),
and SCC in 28 (19.3%) participants. Thus 93.8% of these HIV-
infected Zambian women seeking medical care had abnormal Pap
smears, 76.6% had SIL or SCC, and 53.1% had high-grade SIL or
SCC.
Mean and median CD4
þ lymphocyte counts were 208ml
 1
(s.d.:7177.5) and 165ml
 1 (IQR: 85–299) respectively. Almost two
thirds of the participants (n¼91, 62.7%) had a CD4
þ count
o200ml
 1, 43 (29.6%) had CD4
þ counts between 200–499ml
 1
and 11 (7.5%) had CD4
þ cell counts X500ml
 1. Validation of
results was confirmed with appropriate negative and positive
controls for PCR amplification and b-globin gene detection.
Human papillomavirus DNA was detected in 141 out of 145
(97.2%) participants, while four (2.8%) women had no evidence of
cervicovaginal HPV DNA. High-risk HPV was detected in 131
(90.3%) women. We found a single HPV genotype in 14 (9.7%)
women and multiple (X2) HPV genotypes in 127 (87.5%) women.
The median number of HPV types per woman was 4 (IQR: 2–6),
while the mean was 4.4 (s.d.: 72.8). Of the 37 HPV types
identifiable by the LA-HPV test, all except type 64 were detected in
the 145 samples. The test identified 656 distinct HPV infections in
145 women, of which 350 (53.3%) were HR-HPV while 306 (46.6%)
were LR or UR-HPV types. None of the women carried a HR-HPV
type exclusively (i.e. there was always a LR/UR-HPV present if a
HR-HPV was present). Among the HR types, HPV 52 was found to
be the most prevalent (37.2%). However, the probe for detection of
HPV-52 amplicons in the LA-HPV test is a cross-reactive probe
that also hybridises with types 33, 35, and 58. It was observed that
at least one of these three HR-HPV types was present in 54 (37.2%)
samples along with HPV 52, while the latter was present exclusively
in 11 (7.6%) samples. Human papillomavirus 58 was present in 35
(24.1%) and HPV 53 in 30 (20.7%) samples while types 16, 35 and
45 were equally common (17.2%). Human papillomavirus type 18
(13.1%) was rank-ordered 10th among high risk types.
Among the 28 women with SCC on cervical cytology, at least one
HR-HPV type was present in all women while multiple (X2)
genotypes were present in 22 (78.6%) women. Human papilloma-
virus type 52 (mixed probe as described above) was the most
prevalent in 13 (46.4%), while types 58 and 16 were present in 10
(35.7%). The other HR types in decreasing order of their
prevalence in women with SCC on cytology were HPV types 35
(28.6%), 53 (25%), 31 and 51 (21.4% each), 18 and 45 (17.9% each),
33, 56, 59, and 68 (14.3% each), 39, 36, and 66 (10.7% each), and 73
(3.6%). High-risk type 82 was not detected with SCC. Among LR or
UR HPV types, types 62, 61, 70, and 84 had a prevalence of greater
than 15% in cases with SCC on cytology but none of these types
were present exclusively without the concurrent presence of a HR-
HPV type.
High-risk human papillomavirus types were more likely to be
present with CD4
þ counts o200ml
 1 than with higher counts
(OR: 4.9, 95% CI: 1.4–16.7, P¼0.01). Barring HPV 16 and 39, all
HR types showed greater prevalence in women with CD4
þ counts
o200ml
 1 but only type 51 achieved statistical significance
(P¼0.05), given our sample size of 145. Among HPV-types of
UR, HPV 71 was more likely to be present in women with CD4
þ
counts o200ml
 1 (P¼0.04; Table 1).
The prevalence of HR-HPV types was higher in women with
HSIL or SCC on cervical cytology (OR: 8.0, 95% CI: 1.7–37.4,
P¼0.008). High-risk human papillomavirus 58 and 31 were
significantly more likely in women with HSIL or SCC (P¼0.01
and 0.02 respectively). No other high, low, or UR type was
significantly higher in prevalence in women with HSIL or SCC than
in other women (Table 1).
DISCUSSION
The high prevalence of HPV-DNA in our study (97.2% for any
HPV and 90.3% for any HR-HPV) is one of the highest reported
among an HIV-infected (or any other) population of women
worldwide. Also, HPV types 16 and 18 were not the most prevalent
HR-HPV types and a relatively high frequency of HPV types 52, 58,
35, 53, 31, 51, and 45 was observed in women who had HSIL
lesions or SCC on cytology. This finding has implications in the
eventual implementation of prophylactic HPV vaccines based on
HR-HPV types 16 and 18 (Steinbrook, 2006). Our results add to
those reported in a recent meta-analysis of HPV types among HIV-
infected women (Clifford et al, 2006) and the recent international
data which indicate the increased preponderance of HPV types
other than 16 or 18 among HIV-infected women (Levi et al, 2002;
Bollen et al, 2006; Didelot-Rousseau et al, 2006; Luque et al, 2006).
If cross-reacting immunity is not induced across viral types by
existing vaccines, this will limit their efficacy in immunosup-
pressed women in developing countries whose dominant HR-HPV
types may be other than 16 and 18.
We noted that the majority (87.3%) of participants carried
multiple HPV genotypes and that the mean number of HR types
increased with increasing immunosuppression. Comparable stu-
dies using PCR-based detection of HPV in HIV-infected women
have reported 12–79% of study participants with multiple HPV
types (Levi et al, 2002; Moscicki et al, 2004; Bollen et al, 2006;
Didelot-Rousseau et al, 2006; Hawes et al, 2006; Luque et al, 2006).
This high prevalence may reflect the immune impairment by HIV
that fails to clear HPV, leading to chronic HPV infection. It may
also reflect HR sexual practices of some women as in the case of
drug users and/or sex workers (Vermund et al, 1991; Shah et al,
1997). If HPV replication is more efficient in an immunocompro-
mised host, the resulting higher viral load will make HPV detection
easier and persistence more likely. A higher prevalence of multiple
HPV genotypes can result from HIV-induced upregulation and
persistence of HPV (Vernon et al, 1993; Palefsky et al, 1999;
Moscicki et al, 2004) or from continued sexual exposure to novel
HPV types during periods of severe immunosuppression. Not
surprisingly, we noted no significant association between LR/UR
HPV types and lower CD4
þ cell counts in our participants, nor
any association between LR/UR HPV types and presence of HSIL
or severe abnormalities.
The PGMY09/11 primers used in the LA-HPV test have been
validated for reproducibility and accuracy in diverse populations
(Kornegay et al, 2003; Coutlee et al, 2006). The high-HPV
prevalence in our study reflects both the very high sensitivity of
the LA-HPV test as well as the extraordinary risk faced by Zambian
women living with HIV. The differences in prevalence and
diversity of HPV genotypes in HIV-infected women from different
geographic origins may be due to their differing behavioural,
nutritional, and socioeconomic characteristics or to male factors,
as much as to the immunological status of participants. These
factors need investigation in larger prospective studies around the
world and especially in sub-Saharan Africa where both HIV and
cervical cancer rates are high.
The results reinforce the importance of ensuring adequate
cervical cancer screening services for HIV-infected women in
resource-limited settings like Zambia. They are important given
the recent availability of prophylactic HPV vaccines. Considering
the diversity of HPV types found, HPV vaccine constructs with
polyvalency would be needed for primary prevention of cervical
cancer among HR women in developing country settings.
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